Susquehanna International Group’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.57M Buy
17,900
+5,600
+46% +$1.11M ﹤0.01% 4893
2025
Q4
$2.33M Buy
12,300
+3,300
+37% +$634K ﹤0.01% 5328
2025
Q3
$1.59M Buy
9,000
+3,500
+64% +$520K ﹤0.01% 6269
2025
Q2
$625K Sell
5,500
-1,300
-19% -$139K ﹤0.01% 8651
2025
Q1
$715K Sell
6,800
-5,500
-45% -$622K ﹤0.01% 8094
2024
Q4
$1.32M Sell
12,300
-1,200
-9% -$136K ﹤0.01% 6282
2024
Q3
$1.35M Sell
13,500
-21,400
-61% -$2.15M ﹤0.01% 6150
2024
Q2
$2.94M Sell
34,900
-14,600
-29% -$1.16M ﹤0.01% 4351
2024
Q1
$3.62M Buy
49,500
+28,400
+135% +$2.09M ﹤0.01% 4169
2023
Q4
$1.51M Sell
21,100
-9,500
-31% -$561K ﹤0.01% 6001
2023
Q3
$1.83M Sell
30,600
-2,600
-8% -$171K ﹤0.01% 5300
2023
Q2
$2.39M Sell
33,200
-7,400
-18% -$555K ﹤0.01% 4783
2023
Q1
$2.99M Buy
40,600
+31,500
+346% +$2.24M ﹤0.01% 4337
2022
Q4
$608K Sell
9,100
-83,553
-90% -$5.43M ﹤0.01% 7356
2022
Q3
$4.98M Buy
92,653
+47,769
+106% +$2.81M ﹤0.01% 3155
2022
Q2
$2.5M Sell
44,884
-10,900
-20% -$619K ﹤0.01% 4436
2022
Q1
$3.92M Sell
55,784
-78,067
-58% -$5.66M ﹤0.01% 4105
2021
Q4
$12.9M Buy
133,851
+13,305
+11% +$1.23M ﹤0.01% 2370
2021
Q3
$10.5M Sell
120,546
-83,837
-41% -$6.48M ﹤0.01% 2798
2021
Q2
$16.7M Buy
204,383
+1,764
+0.9% +$147K ﹤0.01% 2262
2021
Q1
$19.3M Buy
202,619
+35,907
+22% +$3.39M ﹤0.01% 1923
2020
Q4
$10.3M Buy
166,712
+118,943
+249% +$6.78M ﹤0.01% 2449
2020
Q3
$2.84M Sell
47,769
-33,343
-41% -$2.28M ﹤0.01% 3965
2020
Q2
$5.66M Sell
81,112
-110,447
-58% -$7M ﹤0.01% 2835
2020
Q1
$8.69M Sell
191,559
-114,293
-37% -$6.48M ﹤0.01% 1897
2019
Q4
$19.9M Buy
305,852
+100,187
+49% +$6.7M 0.01% 1423
2019
Q3
$12.8M Sell
205,665
-195,726
-49% -$12.3M ﹤0.01% 1728
2019
Q2
$28.6M Sell
401,391
-100,669
-20% -$7.41M 0.01% 1039
2019
Q1
$39.4M Buy
502,060
+49,373
+11% +$3.74M 0.02% 756
2018
Q4
$38.3M Buy
452,687
+274,113
+154% +$29.2M 0.02% 704
2018
Q3
$30.6M Buy
178,574
+150,842
+544% +$22.7M 0.01% 1007
2018
Q2
$3.58M Buy
27,732
+17,152
+162% +$1.91M ﹤0.01% 3145
2018
Q1
$1.09M Buy
10,580
+3,206
+43% +$317K ﹤0.01% 5055
2017
Q4
$630K Sell
7,374
-9,137
-55% -$792K ﹤0.01% 6174
2017
Q3
$1.4M Sell
16,511
-152,926
-90% -$12.1M ﹤0.01% 4601
2017
Q2
$12.8M Buy
169,437
+123,912
+272% +$8.67M 0.01% 1500
2017
Q1
$3.01M Sell
45,525
-216,245
-83% -$14.2M ﹤0.01% 3021
2016
Q4
$16.6M Buy
261,770
+219,611
+521% +$13.9M 0.01% 1184
2016
Q3
$2.68M Buy
42,159
+26,930
+177% +$1.98M ﹤0.01% 3075
2016
Q2
$1.13M Sell
15,229
-24,205
-61% -$1.8M ﹤0.01% 4621
2016
Q1
$2.63M Buy
39,434
+6,092
+18% +$370K ﹤0.01% 3255
2015
Q4
$2.25M Sell
33,342
-57,067
-63% -$3.52M ﹤0.01% 3799
2015
Q3
$4.83M Buy
90,409
+7,053
+8% +$428K ﹤0.01% 2715
2015
Q2
$5.25M Buy
83,356
+44,403
+114% +$2.42M ﹤0.01% 2846
2015
Q1
$1.87M Buy
38,953
+9,778
+34% +$375K ﹤0.01% 4436
2014
Q4
$968K Sell
29,175
-82,073
-74% -$2.67M ﹤0.01% 5946
2014
Q3
$3.26M Buy
111,248
+14,106
+15% +$468K ﹤0.01% 3750
2014
Q2
$3.77M Buy
97,142
+36,549
+60% +$1.48M ﹤0.01% 3533
2014
Q1
$2.54M Sell
60,593
-121,668
-67% -$5.07M ﹤0.01% 3922
2013
Q4
$5.98M Buy
182,261
+162,063
+802% +$5.28M ﹤0.01% 2688
2013
Q3
$545K Buy
+20,198
New +$568K ﹤0.01% 6293

Other funds holding LGND

Susquehanna International Group's LGND Position: Q1 2026 in Review

Susquehanna International Group increased its Ligand Pharmaceuticals (LGND) stake by 24% in Q1 2026, buying an estimated $256K and bringing the position to 6,703 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #7170.

Susquehanna International Group first reported a position in LGND in Q2 2013 and has held it in 42 quarters since. The position peaked at $13.5M in Q2 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Susquehanna International Group held 6,703 shares of Ligand Pharmaceuticals worth $1.34M as of Q1 2026.
  • Susquehanna International Group bought 1,294 Ligand Pharmaceuticals shares in Q1 2026, an estimated $256K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7170 holding.
  • Susquehanna International Group first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Susquehanna International Group's Ligand Pharmaceuticals position peaked at $13.5M in Q2 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.